Snooks, Helen, Watkins, Alan, Lyons, Jane, Akbari, Ashley, Bailey, Rowena, Bethell, Lesley, Carson-Stevens, Andrew ORCID: https://orcid.org/0000-0002-7580-7699, Edwards, Adrian ORCID: https://orcid.org/0000-0002-6228-4446, Emery, Helena, Evans, Bridie Angela, Jolles, Stephen, John, Ann, Kingston, Mark, Porter, Alison, Sewell, Bernadette, Williams, Victoria, Lyons, Ronan A. and Dale, Jeremy 2023. Did the UK's public health Shielding policy protect the clinically extremely vulnerable during the Covid-19 pandemic in Wales? Results of EVITE Immunity, a link data retrospective study. Public Health 218 , pp. 12-20. 10.1016/j.puhe.2023.02.008 |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (489kB) | Preview |
Preview |
PDF (Corrigendum)
- Supplemental Material
Download (174kB) | Preview |
Abstract
Introduction The UK shielding policy intended to protect people at highest risk of harm from COVID-19 infection. We aimed to describe intervention effects in Wales at 1 year. Methods Retrospective comparison of linked demographic and clinical data for cohorts comprising people identified for shielding from 23rd March to 21st May 2020; and the rest of the population. Health records were extracted with event dates between 23rd March 2020 and 22nd March 2021 for the comparator cohort and from the date of inclusion until one year later for the shielded cohort. Results The shielded cohort included 117,415 people, with 3,086,385 in the comparator cohort. The largest clinical categories in the shielded cohort were severe respiratory condition (35.5%), immunosuppressive therapy (25.9%) and cancer (18.6%). People in the shielded cohort were more likely to be female, aged >= 50, living in relatively deprived areas, care home residents and frail. The proportion of people tested for COVID-19 was higher in the shielded cohort (OR 1.616; 95% CI 1.597 -1.637), with lower positivity rate IRR 0.716 (95% CI 0.697 – 0.736). The known infection rate was higher in the shielded cohort (5.9% versus 5.7%). People in the shielded cohort were more likely to die (OR 3.683; 95% CI: 3.583 – 3.786); have a critical care admission (OR 3.339; 95% CI: 3.111 – 3.583), hospital emergency admission (OR 2.883; 95% CI: 2.837 – 2.930), Emergency Department attendance (OR 1.893; 95% CI: 1.867 – 1.919) and Common Mental Disorder (OR 1.762; 95% CI: 1.735 – 1.789). Conclusion Deaths and healthcare utilisation were higher amongst shielded people than the general population, as would be expected in the sicker population. Differences in testing rates, deprivation and pre-existing health are potential confounders, however lack of clear impact on infection rates raises questions about the success of shielding and indicates that further research is required to fully evaluate this national policy intervention.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Prime Centre Wales (PRIME) |
Additional Information: | There is a corrigendum for this article at https://doi.org/10.1016/j.puhe.2023.06.001 |
Publisher: | Elsevier |
ISSN: | 0033-3506 |
Funders: | The National Core Studies Immunity Programme, Medical Research Council, Engineering and Physical Sciences Reserach Council, Department of Health and Social Care (England) Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research Wales and Development (Welsh Government), Publich Health Agency (Northern Ireland), British Heart Foundation (BHF) The Wellcome Trust: Administrative Data Research UK which is funded by the Economic and Social Research Council. The work was supported by the Wales COVID-19 Evidence Centre, funded by Health and Care Research Wales |
Date of First Compliant Deposit: | 20 February 2023 |
Date of Acceptance: | 7 February 2023 |
Last Modified: | 11 Oct 2023 19:03 |
URI: | https://orca.cardiff.ac.uk/id/eprint/157179 |
Actions (repository staff only)
Edit Item |